Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through

Lidong Liu1,2,3, Zhiwei Zhang1, Guoxiang Zhang1

  • 1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014, Shandong, People's Republic of China.

Abstract

Insights

Downregulating Peptidylarginine deiminase type II (PADI2) combined with Olaparib suppresses ovarian cancer cell proliferation, migration, and invasion by inhibiting EMT via the JAK2/STAT3 pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Epithelial ovarian cancer (EOC) is a highly lethal gynecological malignancy.
  • Peptidylarginine deiminase type II (PADI2) is implicated in the progression of various cancers, including ovarian cancer.
  • Understanding the role of PADI2 in ovarian cancer (OC) is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the biological role and underlying mechanisms of PADI2 in ovarian cancer.
  • To evaluate the combined effect of PADI2 downregulation and Olaparib treatment on ovarian cancer cells.
  • To elucidate the signaling pathways affected by PADI2 modulation in ovarian cancer.

Main Methods:

  • Gene expression analysis using GEPIA and ONCOMINE.
  • Survival analysis via Kaplan-Meier plotter.
  • In vitro assays including MTT, colony formation, EdU proliferation, wound healing, and Transwell assays.
  • Transcriptome sequencing and Western blot for pathway analysis.
  • In vivo studies using a nude mouse model.

Main Results:

  • PADI2 is upregulated in ovarian cancer, with high expression correlating with poor prognosis.
  • PADI2 knockdown inhibited proliferation, colony formation, migration, and invasion in A2780 and SKOV3 ovarian cancer cells.
  • Combined downregulation of PADI2 and Olaparib treatment significantly attenuated cell viability, migration, and invasion.
  • The combination treatment suppressed epithelial-mesenchymal transition (EMT) and the JAK2/STAT3 signaling pathway.

Conclusions:

  • Downregulation of PADI2 in combination with Olaparib inhibits ovarian cancer cell proliferation, migration, and invasion.
  • This therapeutic strategy acts by suppressing EMT through the JAK2/STAT3 signaling pathway.
  • Targeting PADI2 offers a potential therapeutic avenue for ovarian cancer treatment, particularly in combination with PARP inhibitors like Olaparib.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K